Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 564

1.

Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations.

Ciurea SO, Chilkulwar A, Saliba RM, Chen J, Rondon G, Patel KP, Khogeer H, Shah AR, Randolph BV, Ramos Perez JM, Popat U, Hosing CM, Bashir Q, Mehta R, Al-Atrash G, Im J, Khouri IF, Kebriaei P, Champlin RE.

Blood. 2018 May 16. pii: blood-2018-02-832360. doi: 10.1182/blood-2018-02-832360. [Epub ahead of print] No abstract available.

PMID:
29769261
2.

Infusion of alloanergized donor lymphocytes after CD34-selected haploidentical myeloablative hematopoietic stem cell transplantation.

Davies JK, Brennan LL, Wingard J, Cogle CR, Kapoor N, Shah AJ, Dey BR, Spitzer TR, De Lima M, Cooper LJ, Thall P, Champlin RE, Nadler LM, Guinan EC.

Clin Cancer Res. 2018 May 16. pii: clincanres.0449.2018. doi: 10.1158/1078-0432.CCR-18-0449. [Epub ahead of print]

PMID:
29769208
3.

Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.

Kantarjian HM, DiNardo CD, Nogueras-Gonzalez GM, Kadia TM, Jabbour E, Bueso-Ramos CE, O'Brien SM, Konopleva M, Jain NB, Daver NG, Shpall EJ, Champlin RE, Simkins A, Garcia-Manero G, Keating MJ, Huang X, Cortes JE, Pierce SA, Ravandi F, Freireich EJ.

Cancer. 2018 Apr 12. doi: 10.1002/cncr.31370. [Epub ahead of print]

PMID:
29645075
4.

Fracture risk prediction using FRAX in patients following hematopoietic stem cell transplantation.

Pundole X, Murphy WA, Ebede CC, Karim E, Manocha S, Don-Pedro D, Rondon G, Leung CH, Liu S, Du XL, Champlin RE, Lu H.

Arch Osteoporos. 2018 Apr 4;13(1):38. doi: 10.1007/s11657-018-0453-5.

PMID:
29619576
5.

Neurocognitive deficits in older patients with cancer.

Edwards BJ, Zhang X, Sun M, Holmes HM, Ketonen L, Guha N, Khalil P, Song J, Kesler S, Shah JB, Tripathy D, Valero V, Champlin RE.

J Geriatr Oncol. 2018 Mar 9. pii: S1879-4068(18)30089-4. doi: 10.1016/j.jgo.2018.02.010. [Epub ahead of print]

PMID:
29530493
6.

Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center.

Ciurea SO, Labopin M, Socie G, Volin L, Passweg J, Chevallier P, Beelen D, Milpied N, Blaise D, Cornelissen JJ, Fegueux N, Polge E, Kongtim P, Rondon G, Esteve J, Mohty M, Savani BN, Champlin RE, Nagler A.

Cancer. 2018 May 15;124(10):2134-2141. doi: 10.1002/cncr.31311. Epub 2018 Feb 22.

PMID:
29469961
7.

Delay of alternative antiviral therapy and poor outcomes of acyclovir-resistant herpes simplex virus infections in recipients of allogeneic stem cell transplant - a retrospective study.

Ariza-Heredia EJ, Chemaly RF, Shahani LR, Jang Y, Champlin RE, Mulanovich VE.

Transpl Int. 2018 Jun;31(6):639-648. doi: 10.1111/tri.13142. Epub 2018 Mar 13.

PMID:
29464765
8.

Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia.

Shah MV, Jorgensen JL, Saliba RM, Wang SA, Alousi AM, Andersson BS, Bashir Q, Ciurea SO, Kebriaei P, Marin D, Patel KP, Popat UR, Rezvani K, Rondon G, Shpall EJ, Champlin RE, Oran B.

Biol Blood Marrow Transplant. 2018 Feb 12. pii: S1083-8791(18)30081-8. doi: 10.1016/j.bbmt.2018.02.003. [Epub ahead of print]

PMID:
29448058
9.

Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells.

Valdez BC, Li Y, Murray D, Liu Y, Nieto Y, Champlin RE, Andersson BS.

Oncotarget. 2017 Dec 17;9(3):3908-3921. doi: 10.18632/oncotarget.23386. eCollection 2018 Jan 9.

10.

Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion.

Oran B, Saliba RM, Carmazzi Y, de Lima M, Rondon G, Ahmed S, Alousi A, Andersson BS, Anderlini P, Alvarez M, Bashir Q, Ciurea S, Fernandez-Vina M, Hosing C, Kebriaei P, Korbling M, Cano P, Khouri I, Marin D, Nieto Y, Olson A, Popat U, Rezvani K, Qazilbash M, Shpall EJ, Champlin RE, Cao K.

Blood. 2018 Mar 15;131(11):1248-1257. doi: 10.1182/blood-2017-07-798751. Epub 2018 Jan 31.

PMID:
29386198
11.

Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016.

Al Malki MM, Jones R, Ma Q, Lee D, Reisner Y, Miller JS, Lang P, Hongeng S, Hari P, Strober S, Yu J, Maziarz R, Mavilio D, Roy DC, Bonini C, Champlin RE, Fuchs EJ, Ciurea SO.

Biol Blood Marrow Transplant. 2018 May;24(5):895-908. doi: 10.1016/j.bbmt.2018.01.008. Epub 2018 Jan 12. Review.

PMID:
29339270
12.

Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected and Unmodified Hematopoietic Stem Cell Transplantation.

Tamari R, Oran B, Hilden P, Maloy M, Kongtim P, Papadopoulos EB, Rondon G, Jakubowski AA, Andersson BS, Devlin SM, Ahmed S, Popat UR, Ponce D, Chen J, Sauter C, Young JW, de Lima M, Perales MA, O'Reilly RJ, Giralt SA, Champlin RE, Castro-Malaspina H.

Biol Blood Marrow Transplant. 2018 May;24(5):1079-1087. doi: 10.1016/j.bbmt.2018.01.001. Epub 2018 Jan 8.

PMID:
29325829
13.

Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes.

Brammer JE, Chihara D, Poon LM, Caimi P, de Lima M, Ledesma C, Rondon G, Ciurea SO, Nieto Y, Fanale M, Dabaja B, Maziarz RT, Champlin RE, Hosing C, Oki Y.

Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e41-e50. doi: 10.1016/j.clml.2017.10.001. Epub 2017 Oct 12.

PMID:
29277360
14.

Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit.

Ragon BK, Mehta RS, Gulbis AM, Saliba RM, Chen J, Rondon G, Popat UR, Nieto Y, Oran B, Olson AL, Patel K, Hosing CM, Qazilbash MH, Shah N, Kebriaei P, Shpall EJ, Champlin RE, Alousi AM.

Bone Marrow Transplant. 2018 Mar;53(3):315-325. doi: 10.1038/s41409-017-0034-z. Epub 2017 Dec 21.

PMID:
29269797
15.

Sensitive PCR-based monitoring and early detection of relapsed JAK2 V617F myelofibrosis following transplantation.

Shah MV, Patel KP, Luthra R, Kanagal-Shamanna R, Mehrotra M, Bachegowda LS, Champlin RE, Verstovsek S, Popat UR.

Br J Haematol. 2017 Dec 19. doi: 10.1111/bjh.15059. [Epub ahead of print] No abstract available.

PMID:
29265180
16.

Utility of a patient-reported outcome in measuring functional impairment during autologous stem cell transplant in patients with multiple myeloma.

Shah N, Shi Q, Giralt S, Williams L, Bashir Q, Qazilbash M, Champlin RE, Cleeland CS, Wang XS.

Qual Life Res. 2018 Apr;27(4):979-985. doi: 10.1007/s11136-017-1759-2. Epub 2017 Dec 19.

PMID:
29260444
17.

Fractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience.

Edwards BJ, Sun M, Zhang X, Holmes HM, Song J, Khalil P, Karuturi M, Shah JB, Dinney CP, Gagel RF, Valero V, Champlin RE, Tripathy D, Murphy WA Jr.

Support Care Cancer. 2018 May;26(5):1561-1568. doi: 10.1007/s00520-017-3962-7. Epub 2017 Dec 2.

PMID:
29197959
18.

Prevention of Cytomegalovirus Reactivation in Haploidentical Stem Cell Transplantation.

Hammerstrom AE, Lombardi LR, Pingali SR, Rondon G, Chen J, Milton DR, Chemaly RF, Champlin RE, Gulbis A, Ciurea SO.

Biol Blood Marrow Transplant. 2018 Feb;24(2):353-358. doi: 10.1016/j.bbmt.2017.09.018. Epub 2017 Oct 3.

PMID:
28986189
19.

Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome.

Ciurea SO, Shah MV, Saliba RM, Gaballa S, Kongtim P, Rondon G, Chen J, Wallis W, Cao K, Konopleva M, Daver N, Cortes J, Ravandi F, Alousi A, Ahmed S, Popat U, Parmar S, Bashir Q, Betul O, Hosing C, Shpall EJ, Rezvani K, Khouri IF, Kebriaei P, Champlin RE.

Biol Blood Marrow Transplant. 2017 Sep 14. pii: S1083-8791(17)30713-9. doi: 10.1016/j.bbmt.2017.09.005. [Epub ahead of print]

PMID:
28918304
20.

Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma.

Shah N, Cornelison AM, Saliba R, Ahmed S, Nieto YL, Bashir Q, Parmar S, Hosing C, Popat U, Shpall EJ, Champlin RE, Qazilbash M.

Eur J Haematol. 2017 Dec;99(6):532-535. doi: 10.1111/ejh.12970. Epub 2017 Oct 8.

PMID:
28895206
21.

Impact of Fluid Overload as New Toxicity Category on Hematopoietic Stem Cell Transplantation Outcomes.

Rondón G, Saliba RM, Chen J, Ledesma C, Alousi AM, Oran B, Hosing CM, Kebriaei P, Khouri IF, Shpall EJ, Popat UR, Champlin RE, Ciurea SO.

Biol Blood Marrow Transplant. 2017 Dec;23(12):2166-2171. doi: 10.1016/j.bbmt.2017.08.021. Epub 2017 Aug 24.

PMID:
28844946
22.

Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation.

Ciurea SO, Schafer JR, Bassett R, Denman CJ, Cao K, Willis D, Rondon G, Chen J, Soebbing D, Kaur I, Gulbis A, Ahmed S, Rezvani K, Shpall EJ, Lee DA, Champlin RE.

Blood. 2017 Oct 19;130(16):1857-1868. doi: 10.1182/blood-2017-05-785659. Epub 2017 Aug 23.

PMID:
28835441
23.

Histologic Grade 1 Is Associated With Increased Nonrelapsed Mortality in Lower Gastrointestinal Graft Versus Host Disease.

Im JS, Abraham SC, Saliba RM, Rondon G, Ross WA, Rashid A, Shpall EJ, Popat U, Qazilbash MH, Hosing C, Oran B, Shah N, Tewari P, Nieto Y, Kebriaei P, Champlin RE, Alousi AM.

Am J Surg Pathol. 2017 Nov;41(11):1483-1490. doi: 10.1097/PAS.0000000000000914.

PMID:
28834808
24.

Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review.

Myers AL, Kawedia JD, Champlin RE, Kramer MA, Nieto Y, Ghose R, Andersson BS.

Expert Opin Drug Metab Toxicol. 2017 Sep;13(9):901-923. doi: 10.1080/17425255.2017.1360277. Epub 2017 Aug 17. Review.

PMID:
28766962
25.

HLA-mismatched bone marrow transplantation in severe aplastic anemia.

Bachegowda LS, Shah MV, Veltri LW, Tanase A, Popat U, Anderlini P, Chen J, Rondon G, Champlin RE, Ciurea SO.

Bone Marrow Transplant. 2017 Sep;52(9):1347-1348. doi: 10.1038/bmt.2017.146. Epub 2017 Jul 10. No abstract available.

PMID:
28692030
26.

A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center.

Mohyuddin GR, Faisal MS, Badar T, Shah N, Bashir Q, Patel KK, Hosing C, Popat UR, Rondon G, Delgado R, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH.

Leuk Lymphoma. 2018 Feb;59(2):515-518. doi: 10.1080/10428194.2017.1344906. Epub 2017 Jul 3. No abstract available.

PMID:
28673185
27.

Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.

Veltri LW, Milton DR, Delgado R, Shah N, Patel K, Nieto Y, Kebriaei P, Popat UR, Parmar S, Oran B, Ciurea S, Hosing C, Lee HC, Manasanch E, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q.

Cancer. 2017 Sep 15;123(18):3568-3575. doi: 10.1002/cncr.30770. Epub 2017 May 17.

PMID:
28513828
28.

A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results.

Srour SA, Li S, Popat UR, Qazilbash MH, Lozano-Cerrada S, Maadani F, Alousi A, Kebriaei P, Anderlini P, Nieto Y, Jones R, Shpall E, Champlin RE, Hosing C.

Br J Haematol. 2017 Aug;178(4):561-570. doi: 10.1111/bjh.14731. Epub 2017 May 9.

29.

Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors.

Kongtim P, Adekola K, Milton DR, Ramlal R, Jimenez A, Chen J, Rondon G, Ahmed S, Kebriaei P, Betul O, Hosing CM, Popat U, Khouri I, Jabbour E, Cortes JE, Kantarjian HM, Champlin RE, Ciurea SO.

Leukemia. 2017 Jul;31(7):1654-1657. doi: 10.1038/leu.2017.118. Epub 2017 Apr 12. No abstract available.

PMID:
28400618
30.

The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells.

Valdez BC, Li Y, Murray D, Liu Y, Nieto Y, Champlin RE, Andersson BS.

Leuk Lymphoma. 2017 Nov;58(11):2705-2716. doi: 10.1080/10428194.2017.1306647. Epub 2017 Apr 10.

PMID:
28394191
31.

Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation.

Bachegowda LS, Saliba RM, Ramlal R, Kongtim P, Chen J, Rondon G, Wallis W, Alousi A, Ahmed S, Hosing CM, Parmar S, Qazilbash M, Khouri IF, Bashir Q, Oran B, Popat U, Shpall EJ, Marin D, Rezvani K, Kebriaei P, Champlin RE, Ciurea SO.

Blood. 2017 Jun 1;129(22):3031-3033. doi: 10.1182/blood-2017-02-766154. Epub 2017 Mar 28. No abstract available.

PMID:
28351938
32.

Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.

Yucel OK, Saliba RM, Rondon G, Ahmed S, Alousi A, Bashir Q, Ciurea SO, Popat U, Khouri I, Marin D, Rezvani K, Kebriaei P, Shpall EJ, Champlin RE, Oran B.

Cancer. 2017 Jul 15;123(14):2661-2670. doi: 10.1002/cncr.30632. Epub 2017 Mar 21.

PMID:
28324640
33.

Prognostic Index for Critically Ill Allogeneic Transplantation Patients.

Bayraktar UD, Milton DR, Shpall EJ, Rondon G, Price KJ, Champlin RE, Nates JL.

Biol Blood Marrow Transplant. 2017 Jun;23(6):991-996. doi: 10.1016/j.bbmt.2017.03.003. Epub 2017 Mar 3.

PMID:
28263919
34.

Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphoma.

Ge I, Saliba RM, Maadani F, Popat UR, Qazilbash MH, Ravi Pingali S, Shah N, Ahmed S, Bashir Q, Nieto Y, Champlin RE, Hosing C.

Transfusion. 2017 Apr;57(4):1052-1057. doi: 10.1111/trf.14016. Epub 2017 Feb 10.

PMID:
28185276
35.

Outcomes of children, adolescents, and young adults following allogeneic stem cell transplantation for secondary acute myeloid leukemia and myelodysplastic syndromes-The MD Anderson Cancer Center experience.

Maher OM, Silva JG, Wu J, Liu D, Cooper LJ, Tarek N, Worth L, Lee DA, Petropoulos D, Franklin AR, Zweidler-Mckay P, Wells RJ, Rondon G, Champlin RE, Tewari P.

Pediatr Transplant. 2017 May;21(3). doi: 10.1111/petr.12890. Epub 2017 Feb 3.

PMID:
28160352
36.

Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.

Varma A, Biritxinaga L, Saliba RM, Stich M, Jauch SF, Afrough A, Honhar M, Popat UR, Shafi MA, Shah N, Bashir Q, Dinh Y, Hosing C, Champlin RE, Qazilbash MH.

Biol Blood Marrow Transplant. 2017 Apr;23(4):581-587. doi: 10.1016/j.bbmt.2017.01.005. Epub 2017 Jan 4.

37.

Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation.

Gaballa S, Saliba R, Oran B, Brammer JE, Chen J, Rondon G, Alousi AM, Kebriaei P, Marin D, Popat UR, Andersson BS, Shpall EJ, Jabbour E, Daver N, Andreeff M, Ravandi F, Cortes J, Patel K, Champlin RE, Ciurea SO.

Am J Hematol. 2017 Apr;92(4):331-337. doi: 10.1002/ajh.24632. Epub 2017 Feb 13.

38.

Ibandronate for the prevention of bone loss after allogeneic stem cell transplantation for hematologic malignancies: a randomized-controlled trial.

Lu H, Champlin RE, Popat U, Pundole X, Escalante CP, Wang X, Qiao W, Murphy WA, Gagel RF.

Bonekey Rep. 2016 Oct 19;5:843. doi: 10.1038/bonekey.2016.72. eCollection 2016.

39.

Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients.

Andersson BS, Thall PF, Valdez BC, Milton DR, Al-Atrash G, Chen J, Gulbis A, Chu D, Martinez C, Parmar S, Popat U, Nieto Y, Kebriaei P, Alousi A, de Lima M, Rondon G, Meng QH, Myers A, Kawedia J, Worth LL, Fernandez-Vina M, Madden T, Shpall EJ, Jones RB, Champlin RE.

Bone Marrow Transplant. 2017 Apr;52(4):580-587. doi: 10.1038/bmt.2016.322. Epub 2016 Dec 19.

40.

Poor immune reconstitution is associated with symptomatic BK polyomavirus viruria in allogeneic stem cell transplant recipients.

Abudayyeh A, Hamdi A, Abdelrahim M, Lin H, Page VD, Rondon G, Andersson BS, Afrough A, Martinez CS, Tarrand JJ, Kontoyiannis DP, Marin D, Gaber AO, Oran B, Chemaly RF, Ahmed S, Abudayyeh I, Olson A, Jones R, Popat U, Champlin RE, Shpall EJ, Rezvani K.

Transpl Infect Dis. 2017 Feb;19(1). doi: 10.1111/tid.12632. Epub 2016 Dec 28.

PMID:
27862740
41.

Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic Leukemia.

Srour SA, Milton DR, Bashey A, Karduss-Urueta A, Al Malki MM, Romee R, Solomon S, Nademanee A, Brown S, Slade M, Perez R, Rondon G, Forman SJ, Champlin RE, Kebriaei P, Ciurea SO.

Biol Blood Marrow Transplant. 2017 Feb;23(2):318-324. doi: 10.1016/j.bbmt.2016.11.008. Epub 2016 Nov 14.

42.

Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells.

Hurton LV, Singh H, Najjar AM, Switzer KC, Mi T, Maiti S, Olivares S, Rabinovich B, Huls H, Forget MA, Datar V, Kebriaei P, Lee DA, Champlin RE, Cooper LJ.

Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7788-E7797. Epub 2016 Nov 14.

43.

A subset of virus-specific CD161+ T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML.

Alsuliman A, Muftuoglu M, Khoder A, Ahn YO, Basar R, Verneris MR, Muranski P, Barrett AJ, Liu E, Li L, Stringaris K, Armstrong-James D, Shaim H, Kondo K, Imahashi N, Andersson B, Marin D, Champlin RE, Shpall EJ, Rezvani K.

Blood. 2017 Feb 9;129(6):740-758. doi: 10.1182/blood-2016-05-713347. Epub 2016 Nov 7.

44.

Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results.

Kebriaei P, Bassett R, Lyons G, Valdez B, Ledesma C, Rondon G, Oran B, Ciurea S, Alousi A, Popat U, Patel K, Ahmed S, Olson A, Bashir Q, Shah N, Jones R, Marin D, Rezvani K, Nieto Y, Khouri I, Qazilbash M, Hosing C, Shpall E, Champlin RE, Andersson BS.

Biol Blood Marrow Transplant. 2017 Feb;23(2):285-292. doi: 10.1016/j.bbmt.2016.11.001. Epub 2016 Nov 2.

45.

Imaging of Sleeping Beauty-Modified CD19-Specific T Cells Expressing HSV1-Thymidine Kinase by Positron Emission Tomography.

Najjar AM, Manuri PR, Olivares S, Flores L 2nd, Mi T, Huls H, Shpall EJ, Champlin RE, Turkman N, Paolillo V, Roszik J, Rabinovich B, Lee DA, Alauddin M, Gelovani J, Cooper LJ.

Mol Imaging Biol. 2016 Dec;18(6):838-848.

46.

Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation.

Bock F, Lu G, Srour SA, Gaballa S, Lin HY, Baladandayuthapani V, Honhar M, Stich M, Shah ND, Bashir Q, Patel K, Popat U, Hosing C, Korbling M, Delgado R, Rondon G, Shah JJ, Thomas SK, Manasanch EE, Isermann B, Orlowski RZ, Champlin RE, Qazilbash MH.

Biol Blood Marrow Transplant. 2016 Dec;22(12):2159-2164. doi: 10.1016/j.bbmt.2016.09.003. Epub 2016 Sep 13.

47.

Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.

Gaballa S, Ge I, El Fakih R, Brammer JE, Kongtim P, Tomuleasa C, Wang SA, Lee D, Petropoulos D, Cao K, Rondon G, Chen J, Hammerstrom A, Lombardi L, Alatrash G, Korbling M, Oran B, Kebriaei P, Ahmed S, Shah N, Rezvani K, Marin D, Bashir Q, Alousi A, Nieto Y, Qazilbash M, Hosing C, Popat U, Shpall EJ, Khouri I, Champlin RE, Ciurea SO.

Cancer. 2016 Nov 15;122(21):3316-3326. doi: 10.1002/cncr.30180. Epub 2016 Jul 12.

48.

PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies.

Qazilbash MH, Wieder E, Thall PF, Wang X, Rios R, Lu S, Kanodia S, Ruisaard KE, Giralt SA, Estey EH, Cortes J, Komanduri KV, Clise-Dwyer K, Alatrash G, Ma Q, Champlin RE, Molldrem JJ.

Leukemia. 2017 Mar;31(3):697-704. doi: 10.1038/leu.2016.254. Epub 2016 Sep 22.

49.

Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease.

Issa GC, Kantarjian HM, Yin CC, Qiao W, Ravandi F, Thomas D, Short NJ, Sasaki K, Garcia-Manero G, Kadia TM, Cortes JE, Daver N, Borthakur G, Jain N, Konopleva M, Khouri I, Kebriaei P, Champlin RE, Pierce S, O'Brien SM, Jabbour E.

Cancer. 2017 Feb 1;123(3):459-467. doi: 10.1002/cncr.30376. Epub 2016 Oct 3.

50.

Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma.

Mian I, Milton DR, Shah N, Nieto Y, Popat UR, Kebriaei P, Parmar S, Oran B, Shah JJ, Manasanch EE, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q.

Cancer. 2016 Dec 15;122(24):3831-3837. doi: 10.1002/cncr.30366. Epub 2016 Sep 28.

Supplemental Content

Loading ...
Support Center